Connection

Andrew Kraft to Dasatinib

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Dasatinib.
Andrew Kraft
Connection Strength
0.027
Dasatinib
  1. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.